LeonaBio, Inc. (LONA)
LeonaBio develops experimental drugs for metastatic breast cancer and ALS, based in Bothell, Washington. It last closed at $2.80 on Nov 17, down 13.31% on the day.
Key Stats
Last 12 monthsNot reported for this period.
From LONA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 1 analyst who set a price target on LONA in the past 90 days. The average target is $16.00, with a high of $16.00 and a low of $16.00, compared with the last close of $2.80.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 17 | Citizens | Target lowered | Buy | $17 → $16 |
| Aug 19 | Mizuho | Maintained | Buy | $15 |
| Aug 17 | Citizens | Target lowered | Buy | $18 → $17 |
| Jul 30 | Citizens | Upgrade | Buy | $18 |
| May 27 | Piper Sandler | Initiated | Buy | $20 |
Technical Analysis
The stock is 58% below its 20 day and 84% below its 50 day average. It is 165% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 23), oversold. The nearest support is the Pivot S1 at $2.70, and the nearest resistance the Pivot at $2.85.
| RSI (14) | 23.29 | Oversold below 30 | Oversold |
| MACD | -0.57 | Below its signal line | Bearish |
| Stochastic | 1.2 | Near the bottom of its range | Oversold |
| ADX (14) | 21.7 | Weak trend | |
| Williams %R | -98.1 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -202.2 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −41.3% | Change over 10 sessions | Bearish |
| ATR (14) | $0.52 | Typical daily range, 18.6% of price |
| RSI (14) | 33.77 | Weak, oversold below 30 | Neutral |
| MACD | -1.09 | Below its signal line | Bearish |
| Stochastic | 20.2 | Middle of its range | Neutral |
| ADX (14) | 26.2 | Trending down | |
| Williams %R | -91.2 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -139.2 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −59.5% | Change over 10 sessions | Bearish |
| ATR (14) | $1.50 | Typical daily range, 53.7% of price |
What happened before
See how LONA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How LONA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in LONA in the last 90 days.
LONA Institutional Ownership
Full report →- ●13 buying vs 12 selling
- ▲Held by funds +1.7 pts
- ▲Funds holding +4
- ▼Superinvestors: 1 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 49 | 45 | +8.9% |
| In funds' top 10 | 0 | 0 | – |
| Held by funds | 60.3% | 58.6% | +1.7 pts |
| New / increased | 5 / 8 | 7 / 8 | −13.3% |
| Reduced / sold out | 11 / 1 | 6 / 3 | +33.3% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LONA is in one of them and how their past LONA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered LONA in an article yet. Here's the latest on the wider market.
About LeonaBio
LeonaBio is a biopharmaceutical company based in Bothell, Washington, that develops drug candidates for diseases where current treatments are limited. Its lead candidate, lasofoxifene, is being studied for metastatic breast cancer that has stopped responding well to standard hormone therapy. Its other lead candidate, ATH-1105, is in development for amyotrophic lateral sclerosis, also known as ALS. The company has no approved products yet, and it aims its drugs at patients with these conditions.
- Headquarters
- Bothell, WA


